Article Information
History
- February 19, 2021.
Article Versions
- Version 1 (October 9, 2020 - 15:47).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xiuping Fu,
- Aparna P. Shah,
- Jacqueline Keighron,
- Ta-Chung M. Mou,
- Bruce Ladenheim,
- Jesse Alt,
- Daisuke Fukudome,
- Minae Niwa,
- Kellie Tamashiro,
- Gianluigi Tanda,
- Akira Sawa,
- Jean-Lud Cadet,
- Rana Rais and
- Jay M. Baraban*
- Solomon H. Snyder Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, John Hopkins Drug Discovery, Department of Neurology, Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21205
- Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore MD 21205
- Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35233
- Medication Development Program, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224
- Molecular Neuropsychiatry Research Branch, Intramural Research Program, NIDA/NIH/DHHS, 251 Bayview Boulevard, Baltimore, MD, 21224
- ↵*Corresponding Author; jay.baraban{at}gmail.com